Steffen Daum

Nikolaus Fiebiger Str. 10
Erlangen, BY 91058, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers.

Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers.

Journal: Cancers

Published: December 15, 2021

An Endoplasmic Reticulum Specific Pro-amplifier of Reactive Oxygen Species in Cancer Cells.

An Endoplasmic Reticulum Specific Pro-amplifier of Reactive Oxygen Species in Cancer Cells.

Journal: Angewandte Chemie (International ed. in English)

Published: January 03, 2021

N-Alkylaminoferrocene-Based Prodrugs Targeting Mitochondria of Cancer Cells.

N-Alkylaminoferrocene-Based Prodrugs Targeting Mitochondria of Cancer Cells.

Journal: Molecules (Basel, Switzerland)

Published: April 30, 2020

Hybrids of a 9-anthracenyl moiety and fluorescein as chemodosimeters for the detection of singlet oxygen in live cells.

Hybrids of a 9-anthracenyl moiety and fluorescein as chemodosimeters for the detection of singlet oxygen in live cells.

Journal: Organic & biomolecular chemistry

Published: November 12, 2019

Identification of Boronic Acid Derivatives as an Active Form of N-Alkylaminoferrocene-Based Anticancer Prodrugs and Their Radiolabeling with 18F.

Identification of Boronic Acid Derivatives as an Active Form of N-Alkylaminoferrocene-Based Anticancer Prodrugs and Their Radiolabeling with 18F.

Journal: Bioconjugate chemistry

Published: February 16, 2019

Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors.

Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors.

Journal: Nuclear medicine and molecular imaging

Published: December 13, 2018

Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.

Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: October 23, 2018

ROS-Responsive N-Alkylaminoferrocenes for Cancer-Cell-Specific Targeting of Mitochondria.

ROS-Responsive N-Alkylaminoferrocenes for Cancer-Cell-Specific Targeting of Mitochondria.

Journal: Angewandte Chemie (International ed. in English)

Published: May 23, 2018

Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs.

Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs.

Journal: Angewandte Chemie (International ed. in English)

Published: June 28, 2017

Tuning the structure of aminoferrocene-based anticancer prodrugs to prevent their aggregation in aqueous solution.

Tuning the structure of aminoferrocene-based anticancer prodrugs to prevent their aggregation in aqueous solution.

Journal: Journal of inorganic biochemistry

Published: March 28, 2017

Cancer-Specific, Intracellular, Reductive Activation of Anticancer PtIV Prodrugs.

Cancer-Specific, Intracellular, Reductive Activation of Anticancer PtIV Prodrugs.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: March 16, 2017

Improved synthesis of N-benzylaminoferrocene-based prodrugs and evaluation of their toxicity and antileukemic activity.

Improved synthesis of N-benzylaminoferrocene-based prodrugs and evaluation of their toxicity and antileukemic activity.

Journal: Journal of medicinal chemistry

Published: January 31, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026